Does stanniocalcin predict late breast cancer recurrence, or is it a fish story?
斯钙素是否能预测晚期乳腺癌复发,还是纯属虚构?
基本信息
- 批准号:8692147
- 负责人:
- 金额:$ 18.8万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2014
- 资助国家:美国
- 起止时间:2014-09-26 至 2016-08-31
- 项目状态:已结题
- 来源:
- 关键词:AdipocytesAdjuvant TherapyAffectAntineoplastic AgentsApoptosisAttentionBiological AssayBiological MarkersBiologyBreast Cancer DetectionCalciumCancer PatientCancer PrognosisCancer SurvivorCardiac MyocytesCase-Control StudiesCell DeathCell divisionCellsCharacteristicsClimateClinicalClinical DataColorectal CancerDevelopmentDiagnosisDiseaseDistantEffectivenessEndocrineEndocrine GlandsEnvironmentEquilibriumFaceFishesGillsGrowthHormonesHumanHypoxiaImmunologic SurveillanceIn VitroInvestmentsKidneyLeadLifeLinkMalignant NeoplasmsMeasuresMicrometastasisMindMitochondriaMolecularNeoplasm MetastasisNeuronsNormal CellOocytesOsteichthyesOvumPathway interactionsPatientsPharmaceutical PreparationsPopulationPositioning AttributePrimary NeoplasmProcessProtonsProviderRadiation therapyRecruitment ActivityRecurrenceResearch SupportRiskSTC1 geneSTC2 geneSignal TransductionSolid NeoplasmStagingStratificationStressSurfaceTheca folliculi structureTimeTissuesToxic effectanalogassaultbiobankbreast cancer diagnosiscalcium phosphatecancer recurrencecancer sitecancer therapycell growthchemotherapycohortfollow-upglycosylationheart cellhigh rewardhigh riskhormone therapyhuman STC1 proteinimprovedinorganic phosphateinterstitialmalignant breast neoplasmmolecular markermortalityneoplastic cellnovel therapeuticsparacrinepreventprognosticprogramsprophylacticpublic health relevancescreeningstanniocalcin 2successteleocalcintraittumor
项目摘要
PROJECT SUMMARY/ABSTRACT
Advances in the effectiveness of breast cancer screening and treatment have reduced the breast
cancer mortality rate over the last decades. These advances come from avoided recurrences, but also from
delayed recurrences. The success of chemotherapy, endocrine therapy, and radiation therapy, is typically
measured by a reduction in the risk of recurrence in the first five years after breast cancer diagnosis. Many
recurrences, however, occur late; that is, more than five years after diagnosis. These recurrences erupt from
single dormant cells or micro-metastases where tumor cell growth has been balanced by tumor cell death. How
does a single cell, or a small colony of cells, survive for more than five years in a hostile microenvironment
that, at least at the outset, often includes hypoxic climates induced by cancer therapies?
One likely explanation is that tumors with the capability to recruit stanniocalcin are more likely to survive
in this setting and to recur five or more years after diagnosis. Stanniocalcin is a hormone first discovered in
bony fish, where it regulates the concentration of calcium at the gills. In humans, nerve cells, fat cells, heart
cells, ova, and other long-lived cells recruit stanniocalcin as a survival strategy when they face hypoxic stress,
helping them to live in sometimes harsh conditions by uncoupling proton transport from glycosylation in the
mitochondria. Preliminary human evidence and in vitro studies show that tumor expression of stanniocalcin is a
marker of recurrence risk, and particularly late recurrence risk. We propose, therefore, to use an existing
biobank from ~1700 breast cancer patients (841 with recurrence and 841 matched controls) linked to complete
clinical data and long-term follow-up for recurrence to investigate whether stanniocalcin expression is a specific
marker for late recurrence risk. We will determine whether breast cancer patients with late recurrences were
more likely to have had primary tumors that express stanniocalcin than breast cancer patients with early
recurrences. We will also determine whether the tumor cells of those with late recurrence are more likely to
have retained or acquired the ability to express stanniocalcin than the tumor cells of those with early
recurrence. If we find that stanniocalcin is a specific marker for late breast cancer recurrence, we will seek new
research support to validate the result in a second breast cancer cohort and in a colorectal cancer cohort, and
to investigate drugs to disrupt the pathway.
There is no specific marker for late recurrence risk. A marker that predicts when a recurrence will occur,
rather than whether a recurrence will occur, would change the clinical paradigm for cancers with substantial
late recurrence risk. It would allow personalization of recurrence screening strategies, development of low-
toxicity prophylactic therapies that begin when the late recurrence risk rises, and personalization of existing
adjuvant therapies with regard to time from diagnosis. This R21 high-risk, high-reward project will initiate a
program to identify markers of late recurrence risk and strategies to reduce or ameliorate that risk.
项目总结/摘要
乳腺癌筛查和治疗有效性的进步减少了乳腺癌的发病率。
癌症死亡率在过去的几十年里。这些进步来自避免复发,但也来自
延迟复发化疗、内分泌治疗和放射治疗的成功,
通过乳腺癌诊断后前五年内复发风险的降低来衡量。许多
然而,复发发生较晚,即在诊断后五年以上。这些反复发作的疾病
单个休眠细胞或微转移,其中肿瘤细胞生长已被肿瘤细胞死亡平衡。如何
一个细胞或一个小的细胞群体在一个恶劣的微环境中存活超过五年
至少在一开始,经常包括癌症治疗引起的缺氧气候?
一个可能的解释是,具有招募斯钙素能力的肿瘤更有可能存活
在这种情况下,并在诊断后五年或更长时间内复发。斯钙素是一种激素,
硬骨鱼,在那里它调节鳃的钙浓度。人类的神经细胞脂肪细胞心脏
细胞、卵母细胞和其它长寿细胞在它们面临缺氧应激时募集斯钙素作为存活策略,
通过将质子运输与糖基化解偶联,帮助它们在有时恶劣的条件下生活,
线粒体初步的人类证据和体外研究表明,肿瘤中斯钙素的表达是一个重要的因素。
复发风险的标志物,特别是晚期复发风险。因此,我们建议使用现有的
来自约1700名乳腺癌患者(841名复发患者和841名匹配对照)的生物样本库,
临床数据和长期随访复发,以调查斯钙素表达是否是一种特异性的
晚期复发风险的标志物。我们将确定晚期复发的乳腺癌患者是否
与早期乳腺癌患者相比,
复发。我们还将确定那些晚期复发的肿瘤细胞是否更有可能
保留或获得了表达斯钙素的能力,而不是那些早期肿瘤细胞。
复发如果我们发现斯钙素是晚期乳腺癌复发的特异性标志物,
研究支持,以验证第二个乳腺癌队列和结直肠癌队列的结果,以及
来研究药物来破坏这一通路
没有晚期复发风险的特异性标志物。一种预测复发时间的标记,
而不是是否会复发,将改变癌症的临床模式,
晚期复发风险。它将允许复发筛查策略的个性化,低-
当晚期复发风险上升时开始的毒性预防治疗,以及现有的
辅助治疗与诊断时间有关。这个R21高风险,高回报的项目将启动一个
以识别晚期复发风险标记和降低或改善该风险的策略。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Timothy L. Lash其他文献
Genetic variants in tamoxifen metabolism and early treatment discontinuation among premenopausal breast cancer patients
- DOI:
10.1007/s10549-025-07719-1 - 发表时间:
2025-05-14 - 期刊:
- 影响因子:3.000
- 作者:
Kirsten M. Woolpert;Thomas P. Ahern;James W. Baurley;Maret L. Maliniak;Per Damkier;Anders Kjærsgaard;Lindsay J. Collin;Stephen Hamilton-Dutoit;Trine Tramm;Bent Ejlertsen;Henrik T. Sørensen;Timothy L. Lash;Deirdre P. Cronin-Fenton - 通讯作者:
Deirdre P. Cronin-Fenton
Real-World Risk of Severe Cytopenias in Multiple Myeloma Patients Sequentially Treated with Immunomodulatory Drugs
- DOI:
10.1182/blood-2022-159713 - 发表时间:
2022-11-15 - 期刊:
- 影响因子:
- 作者:
Julie Barberio;Timothy L. Lash;Ajay K. Nooka;Ashley I. Naimi;Rachel E. Patzer;Christopher Kim - 通讯作者:
Christopher Kim
Anthropometric Measures Among Children and Teens With Classic 46,XX Congenital Adrenal Hyperplasia in Relation to Improvements in Diagnosis and Care
- DOI:
10.1016/j.eprac.2024.09.005 - 发表时间:
2024-12-01 - 期刊:
- 影响因子:
- 作者:
Courtney McCracken;Oumaima Kaabi;Mackenzie Crawford;Melissa D. Gardner;Darios Getahun;Michael Goodman;Behzad Sorouri Khorashad;Timothy L. Lash;Douglas Roblin;Suma Vupputuri;Rami Yacoub;Phyllis W. Speiser;Peter A. Lee;David E. Sandberg - 通讯作者:
David E. Sandberg
PRESERVATION OF LEFT VENTRICULAR EJECTION FRACTION WITH STATINS DURING RECEIPT OF ANTHRACYCLINE BASED CHEMOTHERAPY
- DOI:
10.1016/s0735-1097(12)60987-5 - 发表时间:
2012-03-27 - 期刊:
- 影响因子:
- 作者:
Runyawan Chotenimitkhun;Ralph B. D'Agostino Jr;Julia A. Lawrence;Craig A. Hamilton;Jennifer Jordan;Sujethra Vasu;Timothy L. Lash;W. Hundley - 通讯作者:
W. Hundley
Su052 DEVELOPMENT AND TEMPORAL VALIDATION OF A PREDICTION MODEL FOR RISK-STRATIFIED FIT COLORECTAL CANCER SCREENING
- DOI:
10.1016/s0016-5085(21)02128-4 - 发表时间:
2021-05-01 - 期刊:
- 影响因子:
- 作者:
Mette K. Thomsen;Lars Pedersen;Rune Erichsen;Timothy L. Lash;Henrik Toft S⊘rensen;Ellen M. Mikkelsen - 通讯作者:
Ellen M. Mikkelsen
Timothy L. Lash的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Timothy L. Lash', 18)}}的其他基金
Registering Cancer Recurrences in the Georgia Cancer Registry
在佐治亚州癌症登记处登记癌症复发
- 批准号:
10556403 - 财政年份:2019
- 资助金额:
$ 18.8万 - 项目类别:
Registering Cancer Recurrences in the Georgia Cancer Registry
在佐治亚州癌症登记处登记癌症复发
- 批准号:
10330476 - 财政年份:2019
- 资助金额:
$ 18.8万 - 项目类别:
Improving Reproducibility by Incorporating Uncertainty
通过纳入不确定性来提高再现性
- 批准号:
10322751 - 财政年份:2019
- 资助金额:
$ 18.8万 - 项目类别:
Doctoral Student Workshop Co-Sponsored by the Society for Epidemiologic Research
流行病学研究学会联合主办的博士生研讨会
- 批准号:
8838485 - 财政年份:2015
- 资助金额:
$ 18.8万 - 项目类别:
Does stanniocalcin predict late breast cancer recurrence, or is it a fish story?
斯钙素是否能预测晚期乳腺癌复发,还是纯属虚构?
- 批准号:
8935765 - 财政年份:2014
- 资助金额:
$ 18.8万 - 项目类别:
New and integrated perspectives on modification of tamoxifen effectiveness
关于他莫昔芬有效性修改的新的综合视角
- 批准号:
8825461 - 财政年份:2013
- 资助金额:
$ 18.8万 - 项目类别:
New and integrated perspectives on modification of tamoxifen effectiveness
关于他莫昔芬有效性修改的新的综合视角
- 批准号:
8439898 - 财政年份:2013
- 资助金额:
$ 18.8万 - 项目类别:
New and integrated perspectives on modification of tamoxifen effectiveness
关于他莫昔芬有效性修改的新的综合视角
- 批准号:
8642152 - 财政年份:2013
- 资助金额:
$ 18.8万 - 项目类别:
New and integrated perspectives on modification of tamoxifen effectiveness
关于他莫昔芬有效性修改的新的综合视角
- 批准号:
8973797 - 财政年份:2013
- 资助金额:
$ 18.8万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 18.8万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 18.8万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 18.8万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 18.8万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 18.8万 - 项目类别:
Operating Grants